Global Open Surgery Heart Valves Market Size By Type (Mechanical Valves, TAVR Valves), By Application (Hospital, Clinic), By Region, And Segment Forecasts, 2023 to 2032

The Global Open Surgery Heart Valves Market was valued at USD 5.9 billion in 2023 and is projected to reach USD 9.7 billion by 2031, growing at a CAGR of 6.4% during the forecast period of 2023–2031. The market is driven by the rising prevalence of valvular heart diseases, the increasing geriatric population globally, and continuous advancements in open surgical procedures and prosthetic valve technology. Open surgery remains the preferred option in cases where transcatheter procedures are not feasible due to anatomical or medical complexities, particularly in younger and lower-risk patients.

Drivers:

Rising Prevalence of Valvular Heart Disease:

With cardiovascular disease remaining the leading cause of death worldwide, the number of patients diagnosed with valvular heart conditions—such as aortic stenosis and mitral regurgitation—has surged, driving demand for surgical valve replacement procedures.

Technological Advancements in Valve Design:

Innovations in bioprosthetic and mechanical heart valves, including enhanced durability, biocompatibility, and hemodynamic performance, are propelling market adoption. Manufacturers are focusing on next-generation materials and improved surgical techniques to reduce complications and extend device life.

Increase in Cardiothoracic Surgical Expertise:

The increasing availability of specialized cardiac surgery centers and experienced cardiothoracic surgeons, particularly in developing nations, is making open surgery more accessible and safer, thus supporting market growth.

Restraints:

Preference for Minimally Invasive Alternatives:

The growing adoption of transcatheter heart valve procedures such as TAVR (Transcatheter Aortic Valve Replacement), especially in elderly and high-risk populations, is limiting the scope of open surgical procedures.

High Surgical Costs and Longer Recovery:

Open surgery is associated with longer hospital stays, higher costs, and extended recovery periods compared to catheter-based interventions. These factors can deter both patients and healthcare providers from opting for open procedures.

Opportunity:

Expanding Surgical Infrastructure in Emerging Economies:

Developing regions are witnessing major investments in healthcare infrastructure, including cardiac care units and surgical facilities. This trend, combined with growing awareness and access to insurance, is creating significant opportunities for open heart surgery valve providers.

Pediatric and Complex Valve Cases:

Open surgery remains essential in pediatric patients and cases involving multiple valve replacements or congenital defects, where catheter-based treatments are less effective or contraindicated. This niche continues to support market demand.

Market by System Type Insights:

The mechanical heart valves segment held the largest market share in 2023 due to its long-term durability, especially among younger patients who can tolerate lifelong anticoagulation therapy. Meanwhile, the bioprosthetic heart valves segment is expected to grow at a faster pace during the forecast period. These valves are gaining popularity due to reduced need for anticoagulants and improved tissue engineering innovations that enhance longevity and reduce calcification.

Market by End-use Insights:

Hospitals dominated the market in 2023, accounting for more than 60% of global revenue, as they remain the primary settings for open heart surgery procedures. High procedural volumes, access to advanced cardiac surgery infrastructure, and specialist availability contribute to this dominance. However, cardiac specialty centers are anticipated to witness the fastest growth, driven by their focus on complex surgical interventions and postoperative care excellence.

Market by Regional Insights:

North America led the global market in 2023, attributed to the high prevalence of heart valve diseases, robust healthcare infrastructure, and the presence of leading heart valve manufacturers. Europe followed closely, supported by favorable reimbursement policies and increasing geriatric populations. Meanwhile, the Asia-Pacific region is forecasted to register the highest CAGR during the forecast period, driven by improving surgical facilities, rising cardiac disease burden, and a growing pool of trained cardiac surgeons in countries like India and China.

Competitive Scenario:

Key players in the Global Open Surgery Heart Valves Market include:

Edwards Lifesciences Corporation

Medtronic plc

Abbott Laboratories

LivaNova PLC

CryoLife, Inc.

Boston Scientific Corporation

Colibri Heart Valve LLC

Braile Biomédica

Sorin Group

JenaValve Technology, Inc.

These companies are actively investing in product innovation, strategic collaborations, and geographic expansion. For example:

In 2023, Medtronic introduced a next-gen mechanical valve designed for enhanced hemocompatibility.

Edwards Lifesciences received CE Mark approval in 2024 for its new tissue-engineered surgical valve targeting long-term performance in younger populations.

Abbott announced a multi-year partnership with leading cardiovascular centers to advance training and adoption of surgical heart valve technologies in emerging regions.

Scope of Work – Global Open Surgery Heart Valves Market

Report Metric Details

Market Size (2023) USD 5.9 billion

Projected Market Size (2031) USD 9.7 billion

CAGR (2023–2031) 6.4%

Market Segments By System Type (Mechanical, Bioprosthetic), End-use (Hospitals, Cardiac Centers), Region

Growth Drivers Increasing prevalence of valvular heart disease, advancements in valve technology

Opportunities Growth in emerging economies, pediatric & complex case procedures

Key Market Developments:

January 2023: Edwards Lifesciences launched its latest surgical bioprosthetic valve designed to mimic native valve motion for improved outcomes in younger patients.

August 2023: CryoLife, Inc. announced clinical trial results supporting the long-term durability of its On-X mechanical heart valve.

February 2024: Abbott Laboratories expanded its global footprint by opening a new heart valve manufacturing facility in Southeast Asia.

March 2024: Boston Scientific collaborated with leading cardiovascular surgeons to develop AI-powered imaging tools for precise valve placement during surgery.

FAQs:

1) What is the current market size of the Global Open Surgery Heart Valves Market?

The market was valued at USD 5.9 billion in 2023.

2) What is the major growth driver of the Global Open Surgery Heart Valves Market?

Rising prevalence of valvular heart disease and advancements in open surgical valve technologies are the key growth drivers.

3) Which is the largest region during the forecast period in the Global Open Surgery Heart Valves Market?

North America holds the largest market share due to robust infrastructure and high procedure volumes.

4) Which segment accounted for the largest market share in the Global Open Surgery Heart Valves Market?

The mechanical heart valves segment led in 2023 owing to its durability and established use in younger patients.

5) Who are the key market players in the Global Open Surgery Heart Valves Market?

Edwards Lifesciences, Medtronic, Abbott Laboratories, LivaNova, and Boston Scientific are among the top market players.